Assuntos
Protocolos Clínicos , Infecções por Coronavirus , Serviços Médicos de Emergência , Controle de Infecções/organização & administração , Pandemias , Equipamento de Proteção Individual/provisão & distribuição , Pneumonia Viral , Medição de Risco/métodos , Procedimentos Cirúrgicos Operatórios , Betacoronavirus/patogenicidade , COVID-19 , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/prevenção & controle , Procedimentos Clínicos/organização & administração , Procedimentos Clínicos/normas , Transmissão de Doença Infecciosa/prevenção & controle , Serviços Médicos de Emergência/métodos , Serviços Médicos de Emergência/organização & administração , Hong Kong , Humanos , Pandemias/prevenção & controle , Pneumonia Viral/epidemiologia , Pneumonia Viral/prevenção & controle , SARS-CoV-2 , Procedimentos Cirúrgicos Operatórios/classificação , Procedimentos Cirúrgicos Operatórios/métodosRESUMO
Regardless of significant improvement in the area of anti-HBV therapy, resistance and cross-resistance against available therapeutic agents are the major consideration in drug discovery of new agents. The present study is to obtain the insight of the molecular basis of drug resistance conferred by the B and C domain mutations of HBV-polymerase on the binding affinity of four anti-HBV agents [Adefovir (ADV), Tenofovir (TNF), Entecavir (ETV) & 2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA)]. In this regard, homology modeled structure of HBV polymerase was used for minimization, conformational search and Glide XP docking followed by binding energy calculation on wild-type as well as on mutant HBV-polymerases (N236T, L180M+M204V+S202G & A194T). Our studies suggest a significant correlation between the fold resistances and the binding affinity of anti-HBV nucleosides. The domain B residue, L180 is indirectly associated with other active-site hydrophobic residues such as A87, F88 and M204, whereas the domain C residue, M204 is closely associated with sugar/pseudosugar ring positioning in the active site. These hydrophobic residues can directly influence the interaction of the incoming nucleoside triphosphates and change the binding efficacy. The carbohydrate ring part of natural substrate dATP, dGTP, FMCA and ETV, are occupied in similar passion in the grooves of HBV polymerase active site. The exocyclic double bond of Entecavir and FMCA occupies in the backside hydrophobic pocket (made by residues A87, F88, L180and M204), which enhances the overall binding affinity. Additional hydrogen bonding interaction of 2'-fluorine of FMCA with R41 residue of polymerase promotes a positive binding in wild-type as well as in ADVr, ETVr and TNFr with respect to that of entecavir.
Assuntos
Adenina/análogos & derivados , Antivirais/metabolismo , Farmacorresistência Viral , Guanina/análogos & derivados , Organofosfonatos/metabolismo , Tenofovir/metabolismo , Adenina/química , Adenina/metabolismo , Adenina/farmacologia , Adenosina/análogos & derivados , Adenosina/química , Adenosina/metabolismo , Adenosina/farmacologia , Sequência de Aminoácidos , Antivirais/química , Antivirais/uso terapêutico , Sítios de Ligação , Domínio Catalítico , Bases de Dados de Proteínas , Farmacorresistência Viral/efeitos dos fármacos , Farmacorresistência Viral/genética , Produtos do Gene pol/química , Produtos do Gene pol/genética , Produtos do Gene pol/metabolismo , Guanina/química , Guanina/metabolismo , Guanina/farmacologia , Transcriptase Reversa do HIV/química , Transcriptase Reversa do HIV/genética , Transcriptase Reversa do HIV/metabolismo , Hepatite B/tratamento farmacológico , Hepatite B/metabolismo , Hepatite B/patologia , Vírus da Hepatite B/efeitos dos fármacos , Humanos , Ligação de Hidrogênio , Simulação de Dinâmica Molecular , Dados de Sequência Molecular , Mutação , Organofosfonatos/química , Organofosfonatos/farmacologia , Alinhamento de Sequência , Tenofovir/química , Tenofovir/farmacologiaRESUMO
A novel nucleoside analogue, 1-[(2S,4S-2-(hydroxymethyl)-1,3-dioxolan-4-yl]5-vinylpyrimidine-2,4(1H,3H)-dione, or HDVD, was evaluated against a wide variety of herpesviruses and was found to be a highly selective inhibitor of replication of the gammaherpesviruses Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV). HDVD had also a pronounced inhibitory activity against murine herpesvirus 68 (MHV-68) and herpes simplex virus 1 (HSV-1). In contrast, replication of herpesvirus saimiri (HVS), HSV-2, and varicella-zoster virus (VZV) was weakly inhibited by the compound, and no antiviral activity was determined against human cytomegalovirus (HCMV) and rhesus rhadinovirus (RRV). The HDVD-resistant virus phenotype contained point mutations in the viral thymidine kinase (TK) of HSV-1, MHV-68, and HVS isolates. These mutations conferred cross-resistance to other TK-dependent drugs, with the exception of an MHV-68 mutant (E358D) that exhibited resistance only to HDVD. HSV-1 and HVS TK-mutants isolated under selective pressure with bromovinyldeoxyuridine (BVDU) also showed reduced sensitivity to HDVD. Oral treatment with HDVD and BVDU was assessed in an intranasal model of MHV-68 infection in BALB/c mice. In contrast to BVDU treatment, HDVD-treated animals showed a reduction in viral DNA loads and diminished viral gene expression during acute viral replication in the lungs in comparison to levels in untreated controls. The valyl ester prodrug of HDVD (USS-02-71-44) suppressed the latent infection in the spleen to a greater extent than HDVD. In the present study, HDVD emerged as a highly potent antiviral with a unique spectrum of activity against herpesviruses, in particular, gammaherpesviruses, and may be of interest in the treatment of virus-associated diseases.
Assuntos
Antivirais/farmacologia , Gammaherpesvirinae/efeitos dos fármacos , Nucleosídeos/farmacologia , Nucleosídeos de Pirimidina/farmacologia , Pirimidinas/farmacologia , Replicação Viral/efeitos dos fármacos , Animais , Antivirais/metabolismo , Aotidae , Primers do DNA/genética , Fibroblastos , Gammaherpesvirinae/genética , Humanos , Macaca mulatta , Camundongos , Camundongos Endogâmicos BALB C , Estrutura Molecular , Mutação/genética , Células NIH 3T3 , Nucleosídeos/química , Nucleosídeos/metabolismo , Nucleosídeos de Pirimidina/metabolismo , Pirimidinas/química , Pirimidinas/metabolismo , Reação em Cadeia da Polimerase em Tempo Real , Rhadinovirus/efeitos dos fármacos , Especificidade da Espécie , Estatísticas não Paramétricas , Timidina Quinase/genéticaRESUMO
Troxacitabine is a cytotoxic deoxycytidine analogue with an unnatural L-configuration, which is activated by deoxycytidine kinase (dCK). The configuration is responsible for differences in the uptake and metabolism of troxacitabine compared to other deoxynucleoside analogues. The main drawback in the use of most nucleoside anticancer agents originates from their hydrophilic nature, which property requires a high and frequent dosage for an intravenous administration. To overcome this problem several troxacitabine prodrugs modified in the aminogroup with a linear aliphatic chain with a higher lipophilicity were developed. To determine whether these prodrugs have an advantage over Troxacitabine pancreatic cancer cell lines were exposed to Troxacitabine and the lipophilic prodrugs. The addition of linear aliphatic chains to troxacitabine increased sensitivity of pancreatic cancer cell lines to the drug > 100-fold, possibly due to a better uptake and retention of the drug.
Assuntos
Antineoplásicos/química , Antineoplásicos/uso terapêutico , Citosina/análogos & derivados , Dioxolanos/química , Dioxolanos/uso terapêutico , Neoplasias Pancreáticas/tratamento farmacológico , Pró-Fármacos/química , Pró-Fármacos/uso terapêutico , Antineoplásicos/síntese química , Linhagem Celular Tumoral , Citosina/síntese química , Citosina/química , Citosina/uso terapêutico , Dioxolanos/síntese química , Desenho de Fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Pró-Fármacos/síntese químicaRESUMO
In response to cerebral ischemia, neurons activate survival/repair pathways in addition to death cascades. Activation of cyclic AMP-response-element-binding protein (CREB) is linked to neuroprotection in experimental animal models of stroke. However, a role of the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK or MEK), an upstream kinase for CREB, and its relation to CREB phosphorylation in neuroprotection in cerebral ischemia has not been delineated. Previously, we reported that N-acetyl-O-methyldopamine (NAMDA) significantly protected CA1 neurons after transient forebrain ischemia [J Neurosci 19 (1999b) 87.8]. The current study is to investigate whether NAMDA-induced neuroprotection occurs via the activation of ERK and its downstream effector, CREB. NAMDA induced ERK1/2 and CREB phosphorylation with increased survival of HC2S2 hippocampal neurons subjected to oxygen-glucose deprivation. These effects were reversed by U0126, a MEK kinase inhibitor. Similarly, animals treated with NAMDA following ischemia showed increased ERK and CREB phosphorylation in the CA1 subregion of the hippocampus during early reperfusion period with increased number of surviving neurons examined 7 days following ischemia. The NAMDA-induced neuroprotection was abolished by U0126 administered shortly after reperfusion. The results showed that the ERK-CREB signaling pathway might be involved in NAMDA-induced neuroprotection following transient global ischemia and imply that the activation of the pathway in neurons may be an effective therapeutic strategy to treat stroke or other neurological syndromes.
Assuntos
Dopamina/análogos & derivados , Dopamina/farmacologia , Hipocampo/enzimologia , Ataque Isquêmico Transitório/enzimologia , Proteínas Quinases Ativadas por Mitógeno/fisiologia , Neurônios/enzimologia , Animais , Hipóxia Celular/efeitos dos fármacos , Hipóxia Celular/fisiologia , Linhagem Celular , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/metabolismo , Dopamina/uso terapêutico , Inibidores Enzimáticos/farmacologia , Hipocampo/efeitos dos fármacos , Ataque Isquêmico Transitório/tratamento farmacológico , Ataque Isquêmico Transitório/prevenção & controle , Masculino , Proteínas Quinases Ativadas por Mitógeno/antagonistas & inibidores , Neurônios/efeitos dos fármacos , Ratos , Ratos WistarRESUMO
An efficient and practical method for the synthesis of (4R,5R)-4,5-O-isopropylidene-cyclopent-2-enone was developed from D-ribose by using a ring-closing metathesis reaction.
Assuntos
Ciclopentanos/síntese química , Nucleosídeos/síntese química , Ciclopentanos/química , Indicadores e Reagentes , Modelos Moleculares , Nucleosídeos/químicaRESUMO
An improved method for the synthesis of enantiomerically pure D-cyclopentenyl nucleosides has been accomplished and their antiviral activity against orthopox viruses have been evaluated. The key intermediate, L-cyclopent-2-enone 13 was prepared from D-ribose using a ring closing metathesis reaction in eight steps. Among the synthesized nucleosides, the adenine 2 (Neplanocin A), cytosine 14, and 5-F-cytosine 15 analogues exhibited potent anti-orthopox virus activity, including smallpox virus.
Assuntos
Adenosina/análogos & derivados , Antivirais/síntese química , Citidina/análogos & derivados , Nucleosídeos/síntese química , Orthopoxvirus/efeitos dos fármacos , Adenosina/síntese química , Adenosina/farmacologia , Animais , Antivirais/farmacologia , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Vírus da Varíola Bovina/efeitos dos fármacos , Citidina/síntese química , Citidina/farmacologia , Monkeypox virus/efeitos dos fármacos , Nucleosídeos/farmacologia , Relação Estrutura-Atividade , Vírus da Varíola/efeitos dos fármacosRESUMO
Enantiomeric synthesis of D- and L-cyclopentenyl nucleosides and their antiviral activity against HIV and West Nile virus are described. The key intermediate (-)- and (+)-cyclopentenyl alcohols (7 and 15) were prepared from D-gamma-ribonolactone and D-ribose, respectively. Coupling of 7 with appropriately blocked purine and pyrimidine bases via the Mitsunobu reaction followed by deprotection afforded the target L-(+)-cyclopentenyl nucleosides (24-28, 31, 33, and 36). D-(-)-Cyclopentenyl nucleosides (1, 40, 43, and 52-56) were also prepared by a similar procedure for L-isomers from 15. The synthesized compounds were evaluated for their antiviral activity against two RNA viruses: HIV and West Nile virus. Among the synthesized D-(-)-nucleosides, adenine (1, neplanocin A), cytosine (55, CPE-C), and 5-fluorocytosine (56) analogues exhibited moderate to potent anti-HIV activity (EC(50) 0.1, 0.06, and 5.34 microM, respectively) with significant cytotoxicity in PBM, Vero, and CEM cells. Also, cytosine (55) and 5-fluorocytosine (56) analogues exhibited the most potent anti-West Nile virus activity (EC(50) 0.2-3.0 and 15-20 microM, respectively). Among L-(+)-nucleosides, only the cytosine (27) analogue exhibited weak anti-HIV activity (EC(50) 58.9 microM).
Assuntos
Antivirais/síntese química , Ciclopentanos/síntese química , HIV-1/efeitos dos fármacos , Nucleosídeos/síntese química , Vírus do Nilo Ocidental/efeitos dos fármacos , Animais , Fármacos Anti-HIV/síntese química , Fármacos Anti-HIV/química , Fármacos Anti-HIV/farmacologia , Antivirais/química , Antivirais/farmacologia , Aves , Células Cultivadas , Chlorocebus aethiops , Ciclopentanos/química , Ciclopentanos/farmacologia , HIV-1/isolamento & purificação , Humanos , Nucleosídeos/química , Nucleosídeos/farmacologia , Estereoisomerismo , Vírus do Nilo Ocidental/isolamento & purificaçãoRESUMO
Hepatitis B virus (HBV) is the third most common disease after venereal diseases and chickenpox. HBV currently infects 2 billion people in the world, of which 350 million are chronic carriers. At least 1 million chronically infected individuals die each year due to HBV-related diseases, especially cirrhosis and liver cancer. The greatest concern about the diffusion of this virus is in endemic regions in central and southern Africa, South-East Asia and South America, where neonatal exposure results in high mortality rates. Anti-HBV therapy has made important progresses in the last decade, with two approved drugs and a number of other potent agents in the pharmaceutical industry pipeline. Nevertheless, resistance and viral rebound are still major issues in devising a winning strategy, and there is a continuous need of developing new active compounds, as well as therapeutic protocols based on combination therapy and a prophylactic approach. This review will summarize the latest advances in anti-HBV therapy, with particular regard to the latest clinical data on the most significant anti-HBV agents. Issues such as viral resistance and combination therapy will be highlighted.
Assuntos
Antivirais/farmacologia , Vírus da Hepatite B/efeitos dos fármacos , Antivirais/administração & dosagem , Antivirais/uso terapêutico , Quimioterapia Combinada , Hepatite B/tratamento farmacológico , HumanosRESUMO
Computer modeling studies have been performed on the several pairs of D- and L-nucleoside inhibitors with the HIV-1 RT model. Additionally, clinically important M184V mutation, which confers the viral resistance against 3TC and FTC, were studied by the same modeling system.
Assuntos
Antivirais/química , Antivirais/farmacologia , Nucleosídeos/química , Nucleosídeos/farmacologia , Zidovudina/análogos & derivados , Sítios de Ligação , Didesoxinucleotídeos , Transcriptase Reversa do HIV/antagonistas & inibidores , Transcriptase Reversa do HIV/química , Transcriptase Reversa do HIV/genética , Humanos , Modelos Moleculares , Mutação , Inibidores da Transcriptase Reversa/química , Inibidores da Transcriptase Reversa/farmacologia , Estereoisomerismo , Nucleotídeos de Timina/química , Nucleotídeos de Timina/farmacologia , Zidovudina/química , Zidovudina/farmacologiaRESUMO
Nucleoside analogues have been the cornerstone of antiviral therapy over the past thirty years and, currently, 16 commonly used antiviral drugs belong to this category. Although for long time it was believed that only D-nucleosides, possessing a 'natural' stereochemistry, could elicit biological activity, in the last decade this has been proven not to be true. 3TC, a L-nucleoside analogue, is one of the most effective anti-HIV and anti-hepatitis B virus drugs, and nine other L-nucleosides are currently undergoing clinical trials and/or preclinical studies as antiviral or antitumoral agents. This minireview summarizes some biological features and the current status of these promising L-nucleoside analogues.
Assuntos
Antineoplásicos/química , Antineoplásicos/farmacologia , Antivirais/química , Antivirais/farmacologia , Nucleosídeos/química , Nucleosídeos/farmacologia , Antineoplásicos/uso terapêutico , Antivirais/uso terapêutico , HIV-1/efeitos dos fármacos , HIV-1/enzimologia , Vírus da Hepatite B/efeitos dos fármacos , Vírus da Hepatite B/enzimologia , Humanos , Nucleosídeos/uso terapêutico , EstereoisomerismoRESUMO
Carbocyclic 9-deazapurine nucleosides (1-4), a spiranic pyrimidone carbocyclic compound (5), and an unusual carbocyclic isonucleoside (6) were prepared as enantiomerically pure compounds via the key intermediates 10 and 21 from 1,4-gamma-ribonolactone. The key intermediate 10 was prepared by stereoselective reduction with Bu3SnH and then converted to carbocyclic C-ribonucleosides 1, 3, and 4. 2',3'-Didehydro-2',3'-dideoxycarbocyclic 9-deazainosine (2) was prepared from a 2',3'-dimesylate 17 by treatment with Li2Te followed by an acidic deprotection. The key bicyclic intermediate 21 was prepared from a diol 20 by an intramolecular cyclization using CHI3-Ph3P-imidazole and converted to the spiranic compound 5 and an olefinic nucleoside 6 by the construction of the heterocyclic moiety followed by deprotection.
Assuntos
Nucleosídeos/síntese química , Antineoplásicos/síntese química , Antivirais/síntese química , Células Cultivadas , HIV-1/efeitos dos fármacos , Humanos , Inosina/análogos & derivados , Inosina/síntese química , Inosina/farmacologia , Leucócitos Mononucleares/virologia , Nucleosídeos/farmacologiaRESUMO
[reaction: see text] Carbocyclic L-2'deoxynucleosides 17 were synthesized on solid phase in four steps from the appropriately protected intermedate 11. The Mitsunobu reaction was used as a condensation method between the carbocyclic moiety and heterocyclic bases. The regioselectivity of the carbocyclic nucleosides was compared between the solid and solution phase syntheses.
Assuntos
Alanina/isolamento & purificação , Alanina/farmacologia , Compostos Bicíclicos Heterocíclicos com Pontes/isolamento & purificação , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Técnicas de Química Combinatória/métodos , Nucleosídeos/síntese química , Alanina/análogos & derivados , Antineoplásicos/síntese química , Antivirais/síntese química , Solventes/farmacologiaRESUMO
3'-Azido-2',3'-dideoxyuridine (AZDU, Azddu, CS-87) is a nucleoside analog of 3'-azido-3'-deoxythymidine (zidovudine, AZT) that has been shown to inhibit human immunodeficiency virus (HIV-1). AZDU is a potential candidate for treatment of pregnant mothers to prevent prenatal transmission of HIV/AIDS to their unborn children. A rapid and efficient high-performance liquid chromatography (HPLC) method for the determination of AZDU concentrations in rat maternal plasma, amniotic fluid, placental and fetal tissue samples has been developed and validated. Tissue samples were homogenized in distilled water, protein precipitated and extracted using a C-18 solid-phase extraction (SPE) method prior to analysis. Plasma and amniotic fluid samples were protein precipitated with 2 M perchloric acid prior to analysis. Baseline resolution was achieved using a 4.5% acetonitrile in 40 mM sodium acetate (pH 7) buffer mobile phase for amniotic fluid, placenta and fetus samples and with a 5.5% acetonitrile in buffer solution for plasma at flow-rates of 2.0 ml/min. The HPLC system consists of a Hypersil ODS column (150x4.6 mm) with a Nova-Pak C-18 guard column with detection at 263 nm. The method yields retention times of 6.2 and 12.2 min for AZDU and AZT in plasma and 8.3 and 17.6 min for AZDU and AZT in amniotic fluid, fetal and placental tissues. Limits of detection ranged from 0.01 to 0.075 microg/ml. Recoveries ranged from 81 to 96% for AZDU and from 82 to 96% for AZT in the different matrices. Intra-day (n=6) and inter-day (n=9) precision (% RSD) and accuracy (% Error) ranged from 1.48 to 6.25% and from 0.50 to 10.07%, respectively.
Assuntos
Líquido Amniótico/química , Antivirais/sangue , Feto/química , Placenta/química , Zidovudina/análogos & derivados , Zidovudina/sangue , Animais , Antivirais/uso terapêutico , Cromatografia Líquida de Alta Pressão/métodos , Feminino , Estrutura Molecular , Gravidez , Ratos , Ratos Sprague-Dawley , Reprodutibilidade dos TestesRESUMO
We propose a method for restoring the underlying true signal in noisy functional images. The Nadaraya-Watson (NW) estimator described in, e.g., [1] is a classical nonparametric estimator for this problem. Since the true scene in many applications contains abrupt changes between pixels of different types, a modification of the NW estimator is needed. In the data we study, the characteristics of each pixel are given as a function of time. This means that a curve of data points is observed at each pixel. Utilizing this time information, the NW weights can be modified to obtain a weighted average over pixels with the same true value. Theoretical results showing the estimator's properties are developed. Several parameters play an important role for the restoration result. Practical guidelines are given for how these parameters can be selected. Finally, we demonstrate how the method can be successfully applied both to artificial data and Magnetic Resonance Images.
Assuntos
Processamento de Imagem Assistida por Computador , Imageamento por Ressonância Magnética , Encéfalo/anatomia & histologia , Encéfalo/fisiologia , Neoplasias da Mama/patologia , Feminino , Humanos , Imageamento por Ressonância Magnética/métodos , MasculinoRESUMO
Excessive proinflammatory cytokine and NO production by activated microglia play a role in neurodegenerative disorders. To investigate whether the neuroprotectant N-acetyl-O-methyldopamine (NAMDA) downregulates genes associated with microglial activation, we measured gene expression of TNF-alpha, IL-1beta, inducible nitric oxide synthase (NOS2), and an associated cofactor synthesis gene, GTP cyclohydrolase I (GTPCH) in LPS-stimulated microglia cells in the presence or absence of NAMDA. The temporal pattern of cytokine gene expression showed that LPS (0.2 microg/ml) increased TNF-alpha and IL-1beta gene expression at 1 and 3 h, which was repressed by cotreatment of NAMDA. Similarly, LPS also induced GTPCH and NOS2 gene expression at 3 and 6 h, and cotreatment of NAMDA repressed the induction with parallel reduction of nitrite, an oxidative metabolite of nitric oxide. Since transcription factor NF-kappaB is involved in regulating expression of these genes, the effects of NAMDA on NF-kappaB nuclear translocation and DNA binding in immunostimulated microglia were investigated. We found that neither LPS-induced NF-kappaB translocation nor DNA binding activity was affected by cotreatment with NAMDA in BV-2 microglia. On the other hand, NAMDA increased intracellular cAMP levels and potentiated LPS-induced phosphorylated cAMP-responsive element binding protein (pCREB) expression. Treatment with adenosine 3'5'-cyclic monophosphothioate, a specific inhibitor of cAMP-dependent protein kinase (PKA), reversed not only NAMDA-induced pCREB upregulation but also NAMDA-induced repression of TNF-alpha and IL-1beta gene transcription. The data demonstrate that NAMDA represses LPS-induced proinflammatory cytokines gene expression via a cAMP-dependent protein kinase pathway. Thus, repressing proinflammatory cytokines and NOS2 gene expression in activated microglia by NAMDA may provide new therapeutic strategies for ischemic cerebral disease as well as other neurodegenerative diseases.
Assuntos
Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , Dopamina/farmacologia , Interleucina-1/genética , Microglia/enzimologia , Fármacos Neuroprotetores/farmacologia , Óxido Nítrico Sintase/genética , Animais , Linhagem Celular Transformada , AMP Cíclico/metabolismo , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/genética , Proteína Quinase Tipo II Dependente de AMP Cíclico , Dopamina/análogos & derivados , GTP Cicloidrolase/genética , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Regulação Enzimológica da Expressão Gênica/imunologia , Microglia/citologia , Microglia/efeitos dos fármacos , NF-kappa B/metabolismo , Óxido Nítrico Sintase Tipo II , RNA Mensageiro/análise , Transcrição Gênica/efeitos dos fármacos , Transcrição Gênica/imunologia , Fator de Necrose Tumoral alfa/genéticaRESUMO
L: -FMAU [1-(2-fluoro-5-methyl-beta,L-arabinofuranosyl) uracil] has been shown to be an effective inhibitor of hepatitis B virus (HBV) and duck hepatitis B virus replication in cell culture and duck hepatitis B virus replication in acutely infected Peking ducks. The woodchuck hepatitis virus (WHV) and its natural host, the Eastern woodchuck (Marmota monax), have been established as a predictive model for the evaluation of antiviral therapies against chronic HBV infection. In this report, the antiviral activity of l-FMAU against WHV replication in chronically infected woodchucks is described. Four weeks of once-daily oral administration of L-FMAU significantly reduced viremia, antigenemia, intrahepatic WHV replication, and intrahepatic expression of woodchuck hepatitis virus core antigen (WHcAg) in a dose-dependent manner. At the highest dose administered (10 mg/kg/d), significant reductions of intrahepatic WHV RNA and covalently closed circular (ccc)WHV-DNA levels also were observed. The reduction in viremia was remarkably rapid at the higher doses of L-FMAU, with greater than 1,000-fold reductions in WHV-DNA serum levels observed after as little as 2 to 3 days of therapy. Following the withdrawal of therapy, a dose-related delay in viremia rebound was observed. At the highest doses used, viremia remained significantly suppressed in at least one half of the treated animals for 10 to 12 weeks' posttreatment. No evidence of drug-related toxicity was observed in the treated animals. L-FMAU is an exceptionally potent antihepadnaviral agent in vitro and in vivo, and is a suitable candidate for antiviral therapy of chronic HBV infection.
Assuntos
Antivirais/farmacologia , Arabinofuranosiluracila/fisiologia , Expressão Gênica/efeitos dos fármacos , Genes Virais/genética , Vírus da Hepatite B da Marmota/crescimento & desenvolvimento , Vírus da Hepatite B da Marmota/genética , Hepatite B Crônica/virologia , Replicação Viral/efeitos dos fármacos , Animais , Antígenos de Superfície/análise , Arabinofuranosiluracila/análogos & derivados , Replicação do DNA/efeitos dos fármacos , DNA Circular/antagonistas & inibidores , DNA Viral/antagonistas & inibidores , DNA Viral/efeitos dos fármacos , Relação Dose-Resposta a Droga , Antígenos de Hepatite/análise , Vírus da Hepatite B da Marmota/efeitos dos fármacos , Vírus da Hepatite B da Marmota/imunologia , Antígenos da Hepatite C/análise , Marmota , RNA Viral/metabolismo , Fatores de Tempo , Viremia/prevenção & controleRESUMO
A series of unnatural L-nucleosides such as 3TC, FTC and L-FMAU have been found to be potent antiviral agents. The mode of action of L-nucleosides has been found to be similar to that of D-nucleosides as antiviral agents, despite their unnatural stereochemistry, that is, nucleotide formation by kinases followed by interaction with the reverse transcriptase (RT) of HIV or DNA polymerase. To date, the mode of action of nucleoside inhibitors at the molecular level with respect to the active conformations of the 5'-triphosphates as well as the interaction with the RT is not known. Recently, the X-ray crystal structure of the RT-DNA-dTTP catalytic complex has been reported. Computer modeling has been performed for several pairs of D- and L-nucleoside inhibitors using the HIV-1 RT model and crystal coordinate data from a subset of the protein surrounding the deoxynucleoside triphosphate (dNTP) binding pocket region. Results from our modeling studies of D-/L-zidovudine, D-/L-3TC, D-/L-dideoxycytosine triphosphates, dTTP and dCTP show that their binding energies correlate with the reported 50% effective concentrations. Modeling results are also discussed with respect to favorable conformations of each inhibitor at the dNTP site in the polymerization process. Additionally, the clinically important M184V mutation, which confers resistance against 3TC and FTC, was studied with our modeling system. The binding energy patterns of nucleoside inhibitors at the M184V mutation site correlate with the reported antiviral data.
Assuntos
Antivirais/farmacologia , Transcriptase Reversa do HIV/antagonistas & inibidores , HIV-1/efeitos dos fármacos , Nucleosídeos/farmacologia , Inibidores da Transcriptase Reversa/farmacologia , Antivirais/química , Sítios de Ligação/efeitos dos fármacos , Transcriptase Reversa do HIV/genética , HIV-1/enzimologia , Modelos Moleculares , Mutação/genética , Nucleosídeos/química , Inibidores da Transcriptase Reversa/químicaRESUMO
(-)-beta-D-2,6-Diaminopurine dioxolane (DAPD), is a nucleoside reverse transcriptase (RT) inhibitor with activity against human immunodeficiency virus type 1 (HIV-1). DAPD, which was designed as a water-soluble prodrug, is deaminated by adenosine deaminase to give (-)-beta-D-dioxolane guanine (DXG). By using calf adenosine deaminase a K(m) value of 15 +/- 0.7 microM was determined for DAPD, which was similar to the K(m) value for adenosine. However, the k(cat) for DAPD was 540-fold slower than the k(cat) for adenosine. In CEM cells and peripheral blood mononuclear cells exposed to DAPD or DXG, only the 5'-triphosphate of DXG (DXG-TP) was detected. DXG-TP is a potent alternative substrate inhibitor of HIV-1 RT. Rapid transient kinetic studies show the efficiency of incorporation for DXG-TP to be lower than that measured for the natural substrate, 2'-deoxyguanosine 5'-triphosphate. DXG-TP is a weak inhibitor of human DNA polymerases alpha and beta. Against the large subunit of human DNA polymerase gamma a K(i) value of 4.3 +/- 0.4 microM was determined for DXG-TP. DXG showed little or no cytotoxicity and no mitochondrial toxicity at the concentrations tested.
Assuntos
Fármacos Anti-HIV/farmacologia , Dioxolanos/farmacologia , Guanosina/análogos & derivados , HIV-1/efeitos dos fármacos , Pró-Fármacos/farmacologia , Nucleosídeos de Purina/farmacologia , Inibidores da Transcriptase Reversa/farmacologia , Inibidores de Adenosina Desaminase , Células da Medula Óssea/efeitos dos fármacos , Células da Medula Óssea/microbiologia , Células Cultivadas , DNA Viral/biossíntese , Resistência Microbiana a Medicamentos , Inibidores Enzimáticos/farmacologia , Guanosina/farmacologia , HIV-1/enzimologia , HIV-1/ultraestrutura , Humanos , Ácido Láctico/metabolismo , Microscopia Eletrônica , Mitocôndrias/efeitos dos fármacos , Inibidores da Síntese de Ácido NucleicoRESUMO
An asymmetric synthesis of carbocyclic orotidine 15 and its monophosphate 16 were accomplished via the key intermediate cyclopentanone 4, which was prepared from D-gamma-ribonolactone in steps. None of synthesized the compounds inhibited orotidine 5'-monophosphate decarboxylase (EC 4.1.1.23) or orotate phosphoribosyltransferase (EC 2.4.2.10).